Results from a multicenter randomized controlled trial with 360 treatment-experienced HIV-1-infected participants. It compares regimen failure and safety outcomes over 48 weeks between patients who omitted NRTIs versus those who added NRTIs to an optimized antiretroviral regimen. The study was conducted by the ACTG Statistical and Data Analysis Center.
Use Cases
- Analyze the cumulative probability of regimen failure between the omit-NRTIs and add-NRTIs groups over 48 weeks.
- Compare the primary safety outcome of time to initial severe sign, symptom, or laboratory abnormality across treatment arms.
- Examine the proportion of participants achieving an HIV RNA level less than 50 copies/mL by treatment assignment.
- Investigate the mortality outcomes, including the 7 deaths reported in the add-NRTIs group versus none in the omit-NRTIs group.
Strengths
- Data from a randomized controlled trial with 360 participants, providing a basis for comparative analysis.
- 93% of participants completed a 48-week visit, indicating high follow-up rates.
- Study design includes specific noninferiority margin of 15% for the primary efficacy outcome.
Limitations
- Unblinded study design may introduce bias in outcome assessment.
- The authors note the study may not be applicable to resource-poor settings, limiting generalizability.
- Specific column-level data and sample sizes for secondary outcomes are not detailed in the provided input.
Provenance
- Source
- ACTG Statistical and Data Analysis Center, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Collection Method
- Multicenter, randomized, controlled trial (ClinicalTrials.gov: NCT00537394) conducted in outpatient HIV clinics.
- Time Range
- Primary outcomes measured through 48 weeks.
- Freshness
- null
- Geography
- null